BIOATLA, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
BIOATLA, INC. (BCAB) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$5.57 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- BIOATLA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$5.16M.
- BIOATLA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$16.68M.
- BIOATLA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$30.84M.
- BIOATLA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$22.82M.
- BIOATLA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$41.93M.
- BIOATLA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$62.42M.
- BIOATLA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$104.04M.
- BIOATLA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$29.47M, a 562.38% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.57M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | -$5.16M 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | -$41.93M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | -$40.73M 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | -$30.84M 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | -$16.68M 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | -$62.42M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | -$54.95M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | -$49.81M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$30.84M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | -$104.04M 10-K · filed 2025-03-28 | |||
| 2023-09-30 | -$74.22M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$46.81M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$22.82M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$29.47M 10-K · filed 2024-03-26 | |||
| 2022-09-30 | -$66.86M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | -$42.69M 10-Q · filed 2023-08-01 | |||
| 2022-03-31 | -$25.55M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $6.37M 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $31.32M 10-Q · filed 2022-11-04 | |||
| 2021-06-30 | -$31.00M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | -$17.41M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $234.90M 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $53.05M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$3.52M 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | -$3.33M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | -$7.16M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |